Julie Nicole Hamblin

This inventor holds 31 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 14 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Glaxo Group Limited, Glaxosmithkline Intellectual Property Development Limited, Smithkline Beecham Corporation. Active years: 2006-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julie Nicole Hamblin. Retrieved from https://idiyas.com/inventor/julie-nicole-hamblin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 16)

% Patents Active = 48.4

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 14 (Patent Applications = 24)

Average Co-Inventor Count = 8.0

ph-index = 4

Forward Citations = 159(Granted Patents)

Location History:

Hertfordshire, GB (2007)
Stevenage, DE (2007)
Stevenage, GB (2006 - 2023)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

3 out of 2,198

Smithkline Beecham Corporation

patents

4. 1 out of 54

Biota Scientific Management Pty Ltd

Years Active: 2006-2023

Loading Chart...

Areas of Expertise:

P13-Kinase Inhibitors

PI3-Kinases

Indazole Derivatives

Phosphodiesterase Inhibitors

Factor Xa Inhibitors

Oxepinopyrazole

Benzpyrazol Derivatives

Pyrrolidine Derivatives

Quinoline Compounds

Polymorphs

Chemical Compounds

Salts

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11555040 - Oxepinopyrazole derivatives as inhibitors of P13-kinase activity (2023-01-17),

2. 10946025 - Compounds (2021-03-16),

3. 10793559 - Chemical compounds (2020-10-06),

4. 10624898 - Compounds (2020-04-21),

5. 10457674 - Chemical compounds (2019-10-29),

6. 10383879 - Compounds (2019-08-20),

7. 9353098 - Polymorphs and salts (2016-05-31),

8. 9326987 - Indazole derivatives for use in the treatment of influenza virus infection (2016-05-03),

9. 9102668 - Polymorphs and salts (2015-08-11),

10. 8993576 - [object Object] (2015-03-31),

11. 8765743 - Compounds (2014-07-01),

12. 8735390 - Polymorphs and salts (2014-05-27),

13. 8658635 - Benzpyrazol derivatives as inhibitors of PI3 kinases (2014-02-25),

14. 8609657 - Compounds (2013-12-17),

15. 8586590 - Compounds (2013-11-19),

Title: Julie Nicole Hamblin: Pioneering Innovation in Technology

Introduction:

Julie Nicole Hamblin, hailing from Stevenage, GB, is a visionary inventor dedicated to creating a positive impact on society through her technological innovations. With a remarkable portfolio of 31 patents, Julie stands out as a true trailblazer in the world of technology.

Latest Patents:

Among Julie's latest patents is the groundbreaking invention of Oxepinopyrazole derivatives as inhibitors of P13-kinase activity. These compounds, designed as inhibitors of kinase activity - specifically PI3-kinase activity, showcase her expertise in developing cutting-edge solutions in the field of biochemistry.

Career Highlights:

Julie Nicole Hamblin has made significant contributions to the field of technology through her work with esteemed companies like Glaxo Group Limited and Glaxosmithkline Intellectual Property Development Limited. Her innovative spirit and dedication to advancing technology have propelled her to the forefront of her industry.

Collaborations:

Throughout her career, Julie has collaborated with talented individuals such as Joelle Le and Nigel James Parr. These partnerships have not only led to the successful development of new technologies but have also fostered a creative environment where ideas thrive.

Conclusion:

In conclusion, Julie Nicole Hamblin's unwavering passion for innovation and her relentless drive to make a difference in society through her inventions truly set her apart as a pioneer in the world of technology. With a remarkable track record of patents and a commitment to excellence, Julie continues to inspire others in the industry to push the boundaries of what is possible.

Profile summary based on public USPTO records.